Researchers discuss current strategies and challenges in diagnosing and treating intraductal papillary neoplasms (IPNs) of the bile duct and pancreatic duct, which are precursors to pancreatic cancer and cholangiocarcinoma. Modern imaging, biomarkers, and molecular tests are aiding in diagnosis, but treatment should be individualized based on risk assessment. Surgical intervention with chemotherapeutic agents is optimal for malignant cases, especially for the aggressive bile duct IPNs. Conservative management may be suitable for low-risk pancreatic branch-duct lesions. Early diagnosis and individualized treatment are key to effective management.

Journal Article by Pavlidis ET, Galanis IN and Pavlidis TE in World J Gastroenterol

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

read the whole article in World J Gastroenterol

open it in PubMed

Postoperative pancreatic fistula (POPF) is a common complication following pancreatectomy, with over sixty prediction models existing primarily for pancreaticoduodenectomy. However, these models have shown suboptimal accuracy across diverse populations. Future research should focus on developing and validating prediction models for distal and central pancreatectomy, incorporating machine learning and personalized variables. Integration of novel imaging technologies like AI-based radiomics may further enhance predictive accuracy and revolutionize patient care.

Review by Yang F, Windsor JA and Fu DL in World J Gastroenterol

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

read the whole article in World J Gastroenterol

open it in PubMed

Adjuvant chemotherapy following resection for adenocarcinoma from intraductal papillary mucinous neoplasia did not show reduced recurrence rates or improved survival outcomes in a multicenter study. Various chemotherapy regimens were not associated with superior outcomes in any high-risk subgroup, indicating that chemotherapy may not influence recurrence patterns or overall survival in these patients over a median follow-up of 78 months.

Multicenter Study by Lucocq J, Hawkyard J (…) Pandanaboyana S et 50 al. in Br J Surg

© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

read the whole article in Br J Surg

open it in PubMed

Researchers examined the concept of total neoadjuvant therapy (TNT) for pancreatic ductal adenocarcinoma (PDAC), finding that the term “total” is not consistently defined. Although it has gained popularity for its promise of comprehensive preoperative treatment, the current understanding and protocols vary widely, with inconsistent therapy durations and approaches. Among 7 studies reviewed, the length of TNT varied from 2 to 4 months, often including postoperative adjuvant therapy, which contradicts the TNT concept. The findings suggest a lack of clear evidence to support TNT’s use in pancreatic cancer.

Journal Article by Cannas S and Vollmer CM in JAMA Surg

read the whole article in JAMA Surg

open it in PubMed

Minimally invasive surgery for intrahepatic cholangiocarcinoma in patients at high risk of early recurrence provides better disease-free and overall survival compared to open surgery. Laparoscopic approach leads to shorter surgery-adjuvant treatment interval and higher rates of adjuvant therapy initiation within 2 months post-surgery. This study highlights the oncological benefits of laparoscopy in high-risk VER patients.

Journal Article by Ratti F, Maina C (…) Aldrighetti LAM et 5 al. in Ann Surg Oncol

© 2023. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed